Servier Cleared Of Deception Charges From EU Regulators

The European Commission has dropped the charges against Servier, a French independent pharmaceutical company, which accused the French company of providing “misleading and incorrect information” as part of a high-profile review of the pharmaceuticals sector and practices to postpone the market entry of generic drugs. In July 2010, the European Commission sent a ‘statement of

Continue Reading

Servier Signs Agreements with Hybrigenics and Cortex

Servier, the largest French privately-owned pharmaceutical company, has linked up with fellow French firm Hybrigenics to discover first-in-class drugs for a selection of diseases, notably cancer. The companies have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) to be applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular

Continue Reading